Drug Safety expert proficient with the latest and upcoming trends in drug safety required for long term advanced safety analytics advisory. An RNA based platform with multiple indications, applying advanced safety analytics to support the entire portfolio, as opposed to only one indication at a time, is a core strategy for the drug sponsor. Expert […]
READ MORE
Drug Safety Scientist required at 30% of FDA. Must be expert in drug safety statistics. For the particular asset under development the safety profile is extremely strategic. The main competitor product’s safety profile is not ideal but since there are no other treatments it is the primary product for this condition. This asset has similar […]
READ MORE
CNS small molecule sponsor just launched phase 3, looking at commercialization strategy, product launch, etc. Senior Program Management role is soon to be empty. Current thinking is that it may take a while to find the right permanent replacement, looking at experienced executive consultant for the gap period. Must have small molecule NDA experience. Company […]
READ MORE